Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its... see more

TSXV:SQD.H - Post Discussion

SQI Diagnostics Inc > Azova Marketing launch...?
View:
Post by mercedesman on Mar 31, 2022 2:56pm

Azova Marketing launch...?

...targeted for mid - April (per AGM presentation).

Roughly about two weeks from now !


Thus should begin the second major revenue stream.  In total there should be 4 streams...none of which have been revealed iin any meaningful way just yet.

1. Mobile PCR testing (largely via the PBI acquisition with captive Corporate Clients nurtured by PBI)...possibly fueled by the next Covid wave as well (that is startign now in NA).  Fiscal Q2 should be very interesting.

2. Exact Antibody test (now approved by NY for sales accross the US, as long as resullts analyzed in NY labs) Initially the bulk of the Sales will happen via the Azova marketing machine.   Then by other means (other DTC providers, corporate clients, etc.)  Fiscal Q3 and Q4 should be very interesting.

3.  Time to start monetizing transplant Diagnostics. Starting with lungs and UHN, but it sounds like their are major plans to have centers all acrross the US that will use SQI technology to assess, and repair lungs...as well as other organs. Goals are to clean up the donated organs, increase the number of matches, and reduce rate of rejection.  Long Covid may cause this industry to explode. 2022 & 2023?

4. Rali-DX as a critical diagnostic test to determine the severity of infections (not just Covid)  Starts with a Health Canada Approval (any time?).  Reading between the lines, I think that this could be sold as a follow-up test for anyone that tests positive for Covid or Pneumonia, and who wants more information about how worried they should be  (and whether or not they shodul take additional & immediate steps (e.g admission to hopspital, Pfizer antiviral pills, etc.).  It sounds like legacy equipment/machines can be used to process such tests quickly and accurately. Q4 and Q1 and 2023?



Investors might be (make that most likely will be) surprised by the rapid growth in revenues - almost out of no where, and almost over-night !

That and a serious marketing/media launch, should provide the rocket fuel for many Qtrs to come.

MM
Comment by mercedesman on Apr 04, 2022 11:59am
I wonder if the Company/Shares will be marketed to the investment community before.... the major expected jump in revenues to $ 5-$6M for Q2 (3 mo ended March 31) - likely due for release next month Azova starts to open the flood-gates on it's own campaign to induce sales of Exact Antibody tests throughout the US Corrections made to previous post
Comment by mercedesman on Apr 16, 2022 5:27pm
... should be any time now, no?  Azova is a pretty serious organization and should have their ducks in a row, I would think.  Last year, Q2 was released by the 3rd week of May. That should be a market eye opener given the likely material revenue jolt (from the recent PBI acquisition) that will hit SQI books for the first time ( Q2 ending March 31) . I'll take the over on this ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities